Embodiments of the present disclosure belongs to the technical field of animal feed and provides a method for rapidly evaluating metabolizable energy of goose diet by using a technique of simulative digestion gross energy. By using the technical means combining the biological method and the simulative digestion gross energy technique, metabolizable energy of goose feed can be evaluated quickly. Based on the “stomach-small intestine” two-step enzymatic methods, it is the first time to establish a regression equation between the metabolizable energy change and fiber level in the cecum to rectify the value of simulative digestion gross energy in the cecal microbial digestion phase, making the simulative digestion gross energy technique more reasonable in the assessment of metabolizable energy in geese. Results show that the use of simulative digestion gross energy technique to assess the metabolizable energy of goose feed value is highly feasible.

The present disclosure relates to a method of digesting a sample comprising protein, the method comprising: adding the sample to an apparatus containing a buffer and a solid support surface comprising a surface coating, wherein the surface coating immobilizes enzyme while reducing undesired interactions between the sample and the solid support surface; immobilizing enzymes on the surface coating for digestion of the protein of the sample; and heating the sample to complete a heat-assisted digestion of the protein.

The present application relates to systems and methods for assaying presence of large molecule analytes, such as proteins, e.g., antibodies, antigens, receptors, and the like, using a targeted two-dimensional liquid chromatography, tandem mass spectrometry (2D-LC-MS/MS) system, optionally combined with affinity capture. In some aspects, the system is partially or fully automated. In some aspects, the system may allow detection of protein biomarkers (e.g., antibodies or antigens) from clinical or nonclinical biological tissue or fluid samples in the pg/mL to ng/mL range.

Disclosed here are systems and methods for collecting and/or screening of a pancreatic secretion, using a capsule endoscope comprising an imaging system and a trypsin sensor, and a tether coupled to the capsule endoscope.

Embodiments of the present disclosure belongs to the technical field of animal feed and provides a method for rapidly evaluating metabolizable energy of goose diet by using a technique of simulative digestion gross energy. By using the technical means combining the biological method and the simulative digestion gross energy technique, metabolizable energy of goose feed can be evaluated quickly. Based on the “stomach-small intestine” two-step enzymatic methods, it is the first time to establish a regression equation between the metabolizable energy change and fiber level in the cecum to rectify the value of simulative digestion gross energy in the cecal microbial digestion phase, making the simulative digestion gross energy technique more reasonable in the assessment of metabolizable energy in geese. Results show that the use of simulative digestion gross energy technique to assess the metabolizable energy of goose feed value is highly feasible.

Provided herein are methods of processing a polypeptide or protein for analysis, e.g., peptide mapping analysis by mass spectrometry. In exemplary embodiments, the method comprises incubating a digested sample at a mildly acidic pH and/or in the presence of a chaotrope, wherein the digested sample is produced by digesting a polypeptide with a protease to produce a digested sample comprising at least two peptides. In exemplary embodiments, the method comprises digesting the polypeptide with a protease which cleaves C-terminal to tryptophan to produce a digested sample comprising at least two peptides. In exemplary embodiments, the method comprises digesting the polypeptide with trypsin at an enzyme:substrate (E:S) weight ratio of about 1:1 to about 1:15 to produce a digested sample comprising at least two peptides. In exemplary aspects, the digested sample comprises at least one or two peptides each comprising a tyrosine at the C-terminus.

The method according to the present invention for preparing peptide fragments comprises bringing an antibody, which includes a Fc domain immobilized in pores of a porous body, into contact with a protease immobilized on surface of microparticles. Thus, the Fab domain of the antibody is site-specifically cleaved by the protease and a sample containing Fab domain-derived peptide fragments at a high concentration can be obtained. The protease to be used in the present invention is an animal-derived trypsin contaminated with chymotrypsin wherein the chymotrypsin is inactivated and the trypsin is chemically modified at amino group in lysine residues.

A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.

A method of proteolyzing a protein, including immobilizing a protein in at least one pore of a porous body, and contacting the protein immobilized in the pore and a protease immobilized on a solid surface such that the protease selectively accesses a site of the protein and proteolyzes the protein at the site.

A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.